Altimmune's Upcoming Presentation on Pemvidutide
Exciting news is on the horizon for Altimmune, Inc. (NASDAQ: ALT) as they gear up to showcase significant findings from their Phase 2b IMPACT trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH). This presentation will be part of a late-breaking oral podium and poster presentation at The Liver Meeting® 2025, organized by the American Association for the Study of Liver Diseases (AASLD).
Event Details and Presentation Agenda
Altimmune has captured attention with promising 24-week efficacy and safety data from their clinical trial. The company's presentation at the conference, taking place in Washington, D.C., will span from November 7-11, 2025. It will feature key aspects of their research, where attendees can expect to gain insights on important findings that could potentially change treatment paradigms for conditions involving liver diseases.
The presentation details are as follows:
Poster Presentation Insights
- Abstract Title: AI-Based Digital Pathology Analysis: Reduction of Liver Fibrosis from the Pemvidutide Phase 2 IMPACT Trial
- Session: Late-Breaking Posters, with a publication number of 5025
- Date/Time: Saturday, November 8, 2025, during Poster Session II from 1:00 – 2:00 p.m. ET, with ongoing display throughout the conference.
- Presenter: Dr. Julio Gutierrez, an esteemed transplant hepatologist and Senior Medical Director at Altimmune.
Oral Presentation Details
- Abstract Title: A Phase 2 Trial of Pemvidutide in Treating Metabolic Dysfunction-Associated Steatohepatitis
- Session: Late-Breaking Abstracts Parallel Session 3, publication number 5001
- Date/Time: Tuesday, November 11, 2025, at 11:45 a.m. ET
- Presenter: Dr. Mazen Noureddin, a renowned professor of medicine at Houston Methodist Hospital.
Key Focus Areas of the Presentations
The late-breaking presentations will highlight the pivotal outcomes from the IMPACT Phase 2b trial, particularly the 24-week data regarding the reduction in liver fibrosis and other efficacy endpoints aimed at evaluating the impact of pemvidutide on patients. Altimmune is also enthusiastic about the anticipated announcement of the 48-week data later in 2025, which will further enhance our understanding of the drug's long-term benefits.
Understanding the IMPACT Study
The IMPACT trial has enrolled 212 participants with biopsy-confirmed MASH and varying fibrosis stages. Participants in this trial have been randomized to receive weekly subcutaneous injections of pemvidutide in doses of either 1.2 mg, 1.8 mg, or a placebo over 24 weeks, focusing on key effectiveness measures such as MASH resolution without fibrosis worsening, and the reverse.
The study's design also incorporates secondary goals, including evaluating weight loss and assessments of liver fibrosis improvement, making it a well-rounded contribution to the ongoing search for effective treatments.
About Pemvidutide
Pemvidutide is an innovative investigational compound that functions as a dual receptor agonist targeting both GLP-1 and glucagon receptors. This holistic approach aims at not only aiding weight reduction and appetite control but also inducing significant benefits on the liver by reducing fat accumulation, inflammation, and fibrosis, principally in patients suffering from MASH. Given the significant unmet medical need represented by these conditions, pemvidutide has been awarded Fast Track designations by the FDA, increasing hopes for its eventual approval.
About Altimmune
Altimmune is at the forefront of developing next-generation peptide-based therapeutics aimed specifically at liver and cardiometabolic diseases. The company continually strives to innovate, with major focus areas being MASH, Alcohol Use Disorder (AUD), and Alcohol-Associated Liver Disease (ALD). The positive outcomes expected from their clinical studies promise to advance treatment options and improve patient quality of life.
For those looking to learn more about Altimmune's initiatives and products, detailed resources can be found on their website.
Frequently Asked Questions
What is the significance of Altimmune's Phase 2b data on pemvidutide?
The Phase 2b data is crucial as it represents one of the first comprehensive sets of results regarding pemvidutide's impact on MASH patients, shedding light on its efficacy and safety.
When will the presentations take place at The Liver Meeting® 2025?
The presentations are scheduled for November 7-11, 2025, with specific poster and oral sessions on November 8 and November 11, respectively.
Who will be presenting on behalf of Altimmune?
Dr. Julio Gutierrez will present at the poster session, while Dr. Mazen Noureddin will lead the oral presentation.
What is the mechanism of action of pemvidutide?
Pemvidutide functions as a dual receptor agonist, targeting GLP-1 and glucagon receptors, which facilitates weight loss and improves liver health through fat reduction and inflammation management.
What future data can be expected from Altimmune regarding pemvidutide?
Altimmune anticipates releasing 48-week data from the IMPACT study later in 2025, which will provide deeper insights into the long-term effects of pemvidutide.
